Company / SG&A Expense
West Pharmaceutical Services SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$393.6M
FY2025
5-year range
$272.7M / $393.6M
FY2021-FY2025
Trend
+16.3%
vs FY2024
Sector context
#80 of 158
Health Care
What the data says
At $394M, West Pharmaceutical Services's sg&a expense ranks #79 of 158 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $229M in FY2016 to $394M in FY2025.
Based on SEC 10-K filings.
$394M in FY2025 with a 5-year CAGR of +8.4%.
Increased from $353M to $394M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.2%
- 5-Year CAGR
- +8.4%
- 10-Year CAGR
- -
Sector benchmark
#79 of 158 in Health CareTop 49% of 158This company $393.6M Sector average $175.9B
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 16.3% year-over-year.
- Ranks #80 out of 158 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $393.6M | +16.3% |
| FY2024 | $338.5M | -4.2% |
| FY2023 | $353.4M | +17.0% |
| FY2022 | $302.0M | +10.7% |
| FY2021 | $272.7M | +3.7% |
| FY2020 | $262.9M | -3.6% |
| FY2019 | $272.7M | +3.7% |
| FY2018 | $262.9M | +6.9% |
| FY2017 | $246.0M | +7.6% |
| FY2016 | $228.7M | -2.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026